Compare Neurocrine Biosciences Inc (NBIX) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs SOLAI Limited — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Neurocrine Biosciences Inc is far larger — about 1042.5× SOLAI Limited's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| NBIX | SLAI | |
|---|---|---|
Market Cap | $17.40B | $16.69M |
Sector | Health | Technology |
52-Week High | $180.55 | $26.74 |
52-Week Low | $123.10 | $2.74 |
Enterprise Value | $16.49B | $16.33M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
